Brief: Clarity Pharmaceuticals Says Cu-64 SAR-Bombesin Safe, Well Tolerated, Effective In Detecting Prostate Cancer
13/06/2025 14:36
June 13 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX: CLARITY PHARMACEUTICALS LTD - CU-64 SAR-BOMBESIN SAFE, WELL TOLERATED, EFFECTIVE IN DETECTING PROSTATE CANCER CLARITY PHARMACEUTICALS LTD - ONLY TWO PARTICIPANTS HAD MILD ADVERSE EVENTS RELATED TO CU-64 SAR-BOMBESIN CLARITY PHARMACEUTICALS LTD - CU-64 SAR-BOMBESIN IDENTIFIED LESIONS IN 35% OF PARTICIPANTS ON SAME-DAY IMAGING Source text: ID:nPn48H0CHa Further company coverage: CU6.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial